BUSINESS
Pharma wrap: Divis takes a hit, govt restricts stent makers from pulling out
A round-up of the top stories from the pharma sector.
BUSINESS
Glenmark says specialty & innovative products to contribute 30% revenues by 2025
Glemark said it hopes to generate 30 percent of its revenues by 2025 from specialty and innovative products alone. To invest on specialty and innovative pipeline Glenmark said its R&D expenses will stay at roughly 11 – 12 percent of revenues.
BUSINESS
DoP invokes emergency powers to block stent makers from withdrawing products
The Section 3 of DPCO allows the government in emergency cases to direct any manufacturer to ensure adequate availability of drugs or devices.
BUSINESS
NPPA allows Abbott Healthcare to withdraw its popular drug eluting stent
Abbott earlier this month approached NPPA seeking to discontinue sale of its Xience Alpine stent from India citing lack sales viability following capping of prices of medical devices by the drug price regulator early this year.
BUSINESS
Cadila Healthcare enters pact with Pharm-Aid to produce Chickenpox vaccine in Russia
Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan, Cadila Healthcare said in a statement.
BUSINESS
Govt to come up with a universal health insurance soon, consultations on with stakeholders
Providing universal healthcare has been promise of the Narendra Modi government, but the progress has been patchy.
BUSINESS
Biocon's Vizag API plant clears US FDA inspection, shares up
Biocon on Monday said it received zero observations for its active pharmaceutical ingredient (API) plant in Visakhapatnam, Andhra Pradesh.
BUSINESS
Pharma weekly wrap: Pharma stocks gain on investor interest due to cheap valuations
The BSE Healthcare rose 4.44 percent in the past week, the benchmark Sensex gained 1.49 percent
BUSINESS
Timeline of Dr Reddy's regulatory issues and stock price movement
The latest jab is a part of the never-ending saga of regulatory compliance woes the company has been facing starting November 2015
BUSINESS
Law to check unethical marketing practices in pharma faces delay due to legal tangle
The Law Ministry, which was vetting UCPMP, asked the DoP to rework on the draft code as it wasn’t aligned with the legal framework of Essential Commodities Act.
BUSINESS
Biocon gets funding from JDRF to test oral insulin on type-1 diabetes patients
As per the agreement – JDRF or Juvenile Diabetes Research Foundation as it was known will fund Biocon’s global multiple ascending dose study of oral insulin drug candidate to evaluate the safety and tolerability in people with type 1 diabetes.
BUSINESS
No change in IPO plans: Aster DM Healthcare set to refile DRHP
Aster DM Healthcare filed its draft red herring prospectus (DRHP) for IPO in June 2016 with an intention to raise around Rs 2,000 crore, to provide an exit to existing PE investors, repay debt, and invest on expansion.
BUSINESS
Dr Reddy's gets two USFDA observations for Srikakulam plant
The company said was addressing the observations raised by US FDA without specifying the nature of those observations.
BUSINESS
Dishman Pharma gains 20% on US FDA nod to client's cancer drug
"We believe that the increase in the stock price is based upon market estimation that we are one of the suppliers of the API for Zeluja capsules, which got approved by the US FDA," the company said in clarification to stock exchanges. Dishman however did not confirm whether it is the API supplier for Tesaro's Zeluja citing confidentiality agreements.
BUSINESS
Sun Pharma seeks marketing approval from European regulator for psoriasis drug
In July 2016, Almirall entered into a licensing agreement with Sun Pharma for the development and commercialisation of tildrakizumab for psoriasis in Europe.
HEALTH-TRENDS
RS passes HIV-AIDS bill to penalise discrimination, make treatment obligatory
The bill lays down penal provisions for any discrimination practised against a person with HIV/AIDS and breach of confidentiality.
BUSINESS
'Even in US and Europe, we haven't seen such orchestrated action by pharma cos'
In an interview to Moneycontrol, David Keeling of McKinsey & Co says Indian pharmaceutical companies have made a lot of progress in terms of quality control, but there is still a long way to go.
BUSINESS
New e-platform to help India weed out substandard drugs
Unlike the US and Europe, India does not currently have a tracking system for the drug supply chain.
BUSINESS
Sun Pharma buys Bellus Health arm, gets rights to its experimental kidney drug
Shigamab is a monoclonal antibody therapy being developed for the treatment of Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), a rare disease that principally affects the kidneys and often leads to patients requiring acute dialysis.
BUSINESS
Lupin gets US regulator nod for generic oral contraceptive Minastrin 24 Fe
Lupin has received approvals for eight products since January this year and has launched seven products including this one.
BUSINESS
Why Scott Gottlieb, the new US FDA chief, could be good news for Indian drug makers
The US FDA appointment is closely watched by Indian pharmaceutical industry which supplies 40 percent of the generic medications consumed in the US. The generic or copycat drugs account for more than 8 in 10 prescriptions. India has 572 US FDA compliant plants -- the highest outside US.
